Expansion of E-Commerce for Aesthetic Clinic Customers
First written in FY2020-Q2. 8 of 11 entries say "Advanced", first in FY2021-Q2. Latest entry: FY2026-H1.
The whole theme swung hardest in 2022: 2 of 17 companies on the "Worse" side.
12 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「In the aesthetic medicine division, sales of the core series of NAVISION DR, a cosmetics brand sold exclusively through medical institutions, performed steadily, supported in part by the expansion of the aesthetic medicine market. Both sales and profit performed well.」
Against a backdrop of growth in the aesthetic medicine market, sales of NAVISION DR's core series performed steadily, and both sales and profit performed well. - FY2024-Q2AdvancedAnnual report
「In the aesthetic medicine division, the Company continued to focus on expanding sales of NAVISION DR, a cosmetics brand sold exclusively through medical institutions. Sales of the core Whitening and Sunscreen series performed well.」
In the aesthetic medicine business, the Company continued expanding the NAVISION DR brand, and sales of the Whitening and Sunscreen series performed well. - FY2023-Q3AdvancedAnnual report
「In the aesthetic medicine division, 岩城製薬株式会社 began selling its new Cleansing Creamy Gel in August, and the product has been well received.」
The aesthetic medicine division launched Cleansing Creamy Gel in August, and the product was well received. - FY2023-Q2AdvancedAnnual report
「In the aesthetic medicine field, sales exceeded the previous year, driven by the acquisition of new customers.」
The Company acquired new customers in the aesthetic medicine field, resulting in sales above the previous year. - FY2023-Q1AdvancedAnnual report
「In the aesthetic medicine division, sales performed well as a result of strengthened promotion of new products and other products related to aesthetic procedures.」
Sales performed well as the Company stepped up promotional activities for new products and other offerings related to aesthetic medical procedures. - FY2022-Q3AdvancedAnnual report
「We focused on embedding the sales DX launched in December last year, stabilizing production of transferred branded products in April this year, developing new generic products and expanding sales of new products for aesthetic clinics launched in July.」
The company launched new products for aesthetic clinics in July and expanded sales. The transfer of the aesthetic medicine brand-holder function was also cited as an achievement. - FY2022-Q1RestatedAnnual report
「In the aesthetic medicine field, we focused on expanding e-commerce for aesthetic clinic customers.」
The company continued expanding e-commerce for aesthetic clinic customers. - FY2021-Q3AdvancedAnnual report
「Cosmetics for aesthetic clinics performed well as the decline in patient visits ran its course.」
Cosmetics for aesthetic clinics performed well as the decline in patient visits ran its course. - FY2021-Q2AdvancedAnnual report
「Sales of cosmetics for aesthetic clinics remained steady as the decline in patient visits ran its course.」
Sales of cosmetics for aesthetic clinics remained steady as the decline in patient visits ran its course. - FY2021-Q1RestatedAnnual report
「In the aesthetic medicine field, we focused on expanding e-commerce for aesthetic clinic customers.」
The company continued initiatives to expand e-commerce for aesthetic clinic customers. Cosmetics for aesthetic clinics were described as sluggish due to patients refraining from visits. - FY2020-Q2First statedAnnual report
「In the aesthetic medicine field, we focused on expanding e-commerce for aesthetic clinic customers.」
The expansion of e-commerce targeting aesthetic clinic customers was first described as a new sales initiative in the pharmaceutical business.